cerrar
Tagged with Biotech,

Jean-Paul Clozel – CEO, Idorsia
In an exclusive interview, Jean-Paul Clozel explains Idorsia's unique value proposition as a biotech focused on small molecules, how agnosticism in…

2020’s Top 7 Biotech IPOs in Profile
Following the recent news of Remegen's massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to…

Medigen’s Charles Chen on Cell Culture Vaccine Strategies
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what…

US Pharma Innovation Factsheet 2020
In a recent article for PharmaBoardroom, Objective Capital's David Crean took a look at the state of US innovation today and its long term…

Chinese Pharma Share Price Hit; Pfizer-LianBio Linkup; Novo’s…
The latest from Chinese pharma, including a drop in share prices for Chinese vaccine firms in the wake of successful COVID-19 trial results from…

China: Hitgen Aims to Strengthen its “Innovation Foundation”…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical…

China: Green Valley Alzheimer’s Trial; Samsung Biologics…
A roundup of the latest from Chinese pharma, including Green Valley's upcoming US trial for an Alzheimer's drug inspired by algae; Samsung Biologics…

Charles Chen – Vice Chairman & CEO, Medigen Vaccine…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company's COVID-19 vaccine strategy, and what…

Abdi Ibrahim Buys 28.5% Stake in Swiss OM; A Historic Moment for…
When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey's pharma…

Asia-Pacific: Hiring the Right Healthtech CFO Can Be Tough; It…
Robert Hall of Hong Kong-based executive recruitment specialist Ardent Search highlights the key traits and experiences that Asian biotech and medtech…

China: The Pharma Deals Keep Coming
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio…

Chinese Biotech Strategies: Biologics or Small Molecules
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here